Altogether, reinvigorating exhausted CD8<sup>+</sup> T cells in the tumor microenvironment through anti-PD-1×IL-10M represents a promising therapeutic strategy for overcoming anti-PD-1/L1-refractory solid tumors. This evidence concerns the gene CD8A and neoplasm.